• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

What is the Safety Data on Ospemifene Use in Postmenopausal Women?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ospemifene, a SERM, is an oral medication used to treat postmenopausal moderate/severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA)  
  • Simon et al., (Journal of Women’s Health) sought to evaluate the safety of ospemifene

METHODS:

  • Post hoc analysis of safety data pooled from six phase 2 and 3 RCTs  
    • Placebo-controlled, double blinded studies  
    • Treatment-emergent adverse events [TEAEs]) with focus on breast, cardiovascular system, and bone  
    • Majority of women received FDA approved 60 mg dose per day  
    • Duration of medication use ranged between 6 to 52 weeks  
  • Participants 
    • Postmenopausal women 40-80 years 
    • ≤5% vaginal superficial cells on a vaginal smear 
    • At least 1 self-reported, most bothersome (moderate-to-severe) symptom of VVA (dyspareunia or vaginal dryness)  
  • Study assessed TEAEs and in addition 
    • Serious AEs (SAEs), deaths | Discontinuations due to AEs | Specific breast and cardiovascular safety assessments 

RESULTS:

  • Total 2200 randomized 
    • 1242 received 60 mg ospemifene  
  • Median exposure similar  
    • Ospemifene 86 days | Placebo 84 days  
  • Most common treatment-related TEAEs with ospemifene 60 mg  
    • Hot flush (7.5% vs. 2.6% for placebo) 
    • Vaginal discharge (3.8% vs. 0.3%) 
    • Muscle spasms (3.2% vs. 0.9%) 
    • Headache (2.4% vs. 2.4%) 
  • TEAEs leading to discontinuation  
    • Ospemifene: 7.6 vs 3.8% with placebo 
    • Most common TEAE causing discontinuation was hot flash (1% vs 0.3%)  
  • SAEs 
    • 2.6% for ospemifene 60 mg vs 1.8% for placebo 
    • Most unrelated to treatment  
    • Treatment-related SAEs included  
      • Simple endometrial hyperplasia (n=1) | CVA (n = 1, possibly related) | Ovarian cyst (n = 1, possibly related) | DVT (n = 1, probably related and n = 1, possibly related) | Global amnesia (n = 1, possibly related) | Nausea (n = 1, possibly related) in the ospemifene 60 mg group 
  • Breast: Breast cancer and other breast-related TEAEs incidences were comparable between groups  
  • Cardiovascular: TEAE incidence, including DVT, were low with both ospemifene (0.3%) and placebo (0.1%) 
  • Bone: Vertebral and other fracture-related TEAEs were comparable between ospemifene (1.2%) and placebo (1.5% 
  • No deaths reported  

CONCLUSION:

  • Ospemifine was generally well tolerated, with no unexpected safety signals for breast, cardiovascular or breast disease  
  • Hot flashes were the most common reason for discontinuation 
  • Authors report that hot flashes were most frequently experienced in the first 4 weeks and decline with ongoing use  
  • There remains an FDA boxed warning regarding risk for endometrial cancer, DVT and stroke 

Learn More – Primary Sources:

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Prescribing Ospemifene for Postmenopausal Vaginal Atrophy
Treating Postmenopausal Vaginal Atrophy When Estrogen is Not an Option

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site